Annovis Bio Completes Final Patient Visit in Buntanetap's Phase II/III Alzheimer's Trial

Annovis Bio, a company dedicated to the development of innovative treatments for neurodegenerative disorders, has reached a pivotal milestone in its clinical research. The final patient visit for the phase II/III trial of buntanetap, a potential therapy for Alzheimer’s disease (AD), has been completed. This achievement underscores the company's commitment to advancing new solutions for patients with mild to moderate AD.

Maria Maccecchini, Ph.D., the driving force behind Annovis Bio as its Founder, President, and CEO, highlighted the significance of this study's completion, emphasizing the minimal dropout rate and the smooth progression of the trial. Out of the initial 353 participants, 327 successfully finished the trial, which is a randomized, double-blind, placebo-controlled study. The trial investigates the efficacy, safety, and tolerability of buntanetap, with patients receiving one of three doses of the drug or a placebo alongside their standard care for a period of 12 weeks.

Buntanetap is a novel drug candidate that targets the inhibition of multiple neurotoxic proteins, including amyloid beta, tau, alpha synuclein, and TDP43. This approach aims to enhance synaptic transmission, axonal transport, and address neuroinflammation, which are key factors in the degeneration and death of nerve cells. By focusing on these pathways, buntanetap holds promise for reversing the neurodegeneration associated with AD.

Annovis Bio, Inc., based in Malvern, Pennsylvania, is a clinical-stage drug platform company that is uniquely positioned in the field of neurodegeneration. The company is developing a drug that targets both AD and Parkinson’s Disease (PD), with the goal of inhibiting multiple neurotoxic proteins to restore axonal and synaptic activity. This innovative approach is aimed at improving brain function and treating the memory loss and dementia associated with AD, as well as the body and brain dysfunction associated with PD.

The company's focus on improving brain function and treating the associated symptoms of AD and PD is a testament to its dedication to making a significant impact on the lives of those affected by these debilitating diseases. Annovis Bio is poised to continue its mission to develop and bring to market new therapies that can change the course of neurodegenerative diseases.

As the company moves forward with the analysis of the trial data, the anticipation grows for the potential results that could offer new hope for patients and their families. The meticulous cleaning and analysis of the data are currently underway, with the aim of delivering the findings promptly, as stated by Melissa Gaines, Senior Vice President of Clinical Operations.

Annovis Bio's dedication to clinical research and drug development is evident in its pursuit of innovative therapies for neurodegenerative diseases. The company's efforts are a beacon of hope for those affected by these challenging conditions, and the completion of the phase II/III trial is a significant step towards realizing the potential of buntanetap as a new treatment option.